Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Open access

Abstract

BACKGROUND: Aging frailty, characterized by decreased physical and immunological functioning, is associated with stem cell depletion. Human allogeneic mesenchymal stem cells (allo-hMSCs) exert immunomodulatory effects and promote tissue repair. METHODS: This is a randomized, double-blinded, dose-finding study of intravenous allo-hMSCs (100 or 200-million [M]) vs placebo delivered to patients (n = 30, mean age 75.5 ± 7.3) with frailty. The primary endpoint was incidence of treatment-emergent serious adverse events (TE-SAEs) at 1-month postinfusion. Secondary endpoints included physical performance, patient-reported outcomes, and immune markers of frailty measured at 6 months postinfusion. RESULTS: No therapy-related TE-SAEs occurred at 1 month. Physical performance improved preferentially in the 100M-group; immunologic improvement occurred in both the 100M- and 200M-groups. The 6-minute walk test, short physical performance exam, and forced expiratory volume in 1 second improved in the 100M-group (p = .01), not in the 200M- or placebo groups. The female sexual quality of life questionnaire improved in the 100M-group (p = .03). Serum TNF-α levels decreased in the 100M-group (p = .03). B cell intracellular TNF-α improved in both the 100M- (p < .0001) and 200M-groups (p = .002) as well as between groups compared to placebo (p = .003 and p = .039, respectively). Early and late activated T-cells were also reduced by MSC therapy. CONCLUSION: Intravenous allo-hMSCs were safe in individuals with aging frailty. Treated groups had remarkable improvements in physical performance measures and inflammatory biomarkers, both of which characterize the frailty syndrome. Given the excellent safety and efficacy profiles demonstrated in this study, larger clinical trials are warranted to establish the efficacy of hMSCs in this multisystem disorder. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov: CRATUS (#NCT02065245).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/gerona/glx137

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Study flow chart. Patient screening, follow-up, and randomization in a 1:1:1 fashion to either the 100M-group, 200M-group, or placebo. M = Million.
Figure 1. Study flow chart. Patient screening, follow-up, and randomization in a 1:1:1 fashion to either the 100M-group, 200M-group, or placebo. M = Million.CC BY · PubMed Central
Figure 2. Physical markers of frailty. (A) Six-minute walk test (6MWT) increased in mean meters walked in the 100M-group from baseline to 6 months (p = .011) but not the 200M-group (p = .263) or placebo (p = .112). (B) Short physical performance battery (SPPB) was significant for an overall improvement in the median total score in the 100M-group from baseline to 6 months (p = .031) but not in the 200M-group (p = .812) or placebo (p = .875). (C) Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire was significant for a reduced median total caloric expenditure per week at moderate intensity from baseline to 6 months in the 200M-group (p = .008) and placebo (p = .039), but not in the 100M-group (p = .641). (D) Forced expiratory volume after 1 second (FEV1) improved in mean liters from baseline to 6 months in the 100M-group (p = .025) without changes noted in the 200M-group (p = .259) or placebo (p = .883). * indicates p ≤ .05.
Figure 2. Physical markers of frailty. (A) Six-minute walk test (6MWT) increased in mean meters walked in the 100M-group from baseline to 6 months (p = .011) but not the 200M-group (p = .263) or placebo (p = .112). (B) Short physical performance battery (SPPB) was significant for an overall improvement in the median total score in the 100M-group from baseline to 6 months (p = .031) but not in the 200M-group (p = .812) or placebo (p = .875). (C) Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire was significant for a reduced median total caloric expenditure per week at moderate intensity from baseline to 6 months in the 200M-group (p = .008) and placebo (p = .039), but not in the 100M-group (p = .641). (D) Forced expiratory volume after 1 second (FEV1) improved in mean liters from baseline to 6 months in the 100M-group (p = .025) without changes noted in the 200M-group (p = .259) or placebo (p = .883). * indicates p ≤ .05.CC BY · PubMed Central
Figure 3. Immune biomarkers in frailty. All time points are from baseline to 6 months except for TNF-α which begins on Day 1 (infusion) through 6 months. (A) Early T-cell activation (CD3, CD69) were reduced as a percent change from baseline to 6 months in the 200M-group (p = .004), but not the 100M-group (p = .269) or placebo (p = .0797). (B) Late T-cell activation (CD3, CD25) was reduced as a percent change from baseline to 6 months in the 100M and 200M-groups (p = .007 and p = .048 respectively), but not in the placebo (p = .119). (C) % CD8 T-cells decreased from baseline to 6 months in the 200M-group (p = .022) and no changes were noted in the 100M-group (p = .978) or placebo (p = .0797). (D) CD4/CD8 ratio increased from baseline to 6 months in the 200M-group (p = .014) and no changes were found in the 100M-group (p = .609) or placebo (p = .104). (E) Serum TNF-α decreased in pg/mL from baseline to 6 months in the 100M-group (p = .031) without a change in the 200M-group (p = .129) or placebo (p = .094). (F) %B cells expressing intracellular TNF-α decreased from baseline to 6 months in the 100M (p < .0001) and 200M-groups (p = .002) without a significant change in placebo (p = .869). * indicates p ≤ .05.
Figure 3. Immune biomarkers in frailty. All time points are from baseline to 6 months except for TNF-α which begins on Day 1 (infusion) through 6 months. (A) Early T-cell activation (CD3, CD69) were reduced as a percent change from baseline to 6 months in the 200M-group (p = .004), but not the 100M-group (p = .269) or placebo (p = .0797). (B) Late T-cell activation (CD3, CD25) was reduced as a percent change from baseline to 6 months in the 100M and 200M-groups (p = .007 and p = .048 respectively), but not in the placebo (p = .119). (C) % CD8 T-cells decreased from baseline to 6 months in the 200M-group (p = .022) and no changes were noted in the 100M-group (p = .978) or placebo (p = .0797). (D) CD4/CD8 ratio increased from baseline to 6 months in the 200M-group (p = .014) and no changes were found in the 100M-group (p = .609) or placebo (p = .104). (E) Serum TNF-α decreased in pg/mL from baseline to 6 months in the 100M-group (p = .031) without a change in the 200M-group (p = .129) or placebo (p = .094). (F) %B cells expressing intracellular TNF-α decreased from baseline to 6 months in the 100M (p < .0001) and 200M-groups (p = .002) without a significant change in placebo (p = .869). * indicates p ≤ .05.CC BY · PubMed Central
Figure 4. Sexual quality of life-female (SQOL-F) questionnaire. There was a mean increase in the 100M-group (p = .0348) from baseline to 6 months as compared to the 200M-group (p = .882) and placebo (p = .941). * indicates p ≤ .05.
Figure 4. Sexual quality of life-female (SQOL-F) questionnaire. There was a mean increase in the 100M-group (p = .0348) from baseline to 6 months as compared to the 200M-group (p = .882) and placebo (p = .941). * indicates p ≤ .05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 186

Metadata

Authors
Tompkins, B. A., DiFede, D. L., Khan, A., Landin, A. M., Schulman, I. H., Pujol, M. V., Heldman, A. W., Miki, R., Goldschmidt-Clermont, P. J., Goldstein, B. J., Mushtaq, M., Levis-Dusseau, S., Byrnes, J. J., Lowery, M., Natsumeda, M., Delgado, C., Saltzman, R., Vidro-Casiano, M., Da Fonseca, M., Golpanian, S., Premer, C., Medina, A., Valasaki, K., Florea, V., Anderson, E., El-Khorazaty, J., Mendizabal, A., Green, G., Oliva, A. A., & Hare, J. M.
Affiliations
  • The Interdisciplinary Stem Cell Institute,
  • University of Miami (US)
  • Department of Medicine, University of Miami Miller School of Medicine, Florida.
  • Department of Surgery, and
  • Emmes (United States) (US)
  • Longeveron LLC, Miami, Florida.
Corresponding author
Hare, Joshua M
Venue
The Journals of Gerontology: Series A
Published
2017-07-17
Volume
72
Issue
11
Pages
1513-1522
ISSN
  • 1079-5006 (ISSN-L)
  • 1758-535X
OpenAlex
W2734481251
Cited by
169
References
49
Citations by year
2026: 22 · 2025: 16 · 2024: 24 · 2023: 16 · 2022: 14 · 2021: 27 · 2020: 14 · 2019: 21 · 2018: 11 · 2017: 3
FWCI
7.70
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • The Journals of Gerontology Series A (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Greater South Information System
Funders
Starr Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
allogeneic mesenchymal stem cells, frailty, aging, intravenous cell therapy, physical performance, immunomodulation, TNF-α, inflammation, T cell activation, B cells, quality of life, stem cell dose, safety
MeSH terms
Aged, Aged, 80 and over, Aging, Double-Blind Method, Female, Follow-Up Studies, Humans, Immunity, Innate, Infusions, Intravenous, Male, Middle Aged, Transplantation, Homologous, Frail Elderly, Treatment Outcome, Regenerative Medicine, Mesenchymal Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial. https://app.cochat.ai/papers/10.1093/gerona/glx137
The paper
Tompkins, B. A., DiFede, D. L., Khan, A., Landin, A. M., Schulman, I. H., Pujol, M. V., Heldman, A. W., Miki, R., Goldschmidt-Clermont, P. J., Goldstein, B. J., Mushtaq, M., Levis-Dusseau, S., Byrnes, J. J., Lowery, M., Natsumeda, M., Delgado, C., Saltzman, R., Vidro-Casiano, M., Da Fonseca, M., . . . Hare, J. M. (2017). Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial. The Journals of Gerontology: Series A. https://doi.org/10.1093/gerona/glx137

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.